Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Bicara Therapeutics, with 9 buy, 2 strong-buy, 3 hold and 1 sell rating. The average 12-month price target is $32.64.
• Recent analysts raised their targets, including BTIG Research to $39 and Wedbush to $33, while Cantor Fitzgerald and BMO Capital Markets maintained bullish ratings.
• Bicara shares opened at $22.81, well below the analyst consensus target, while the company reported a quarterly loss of $0.82 per share. Insiders sold 125,500 shares worth about $3.48 million over the past three months, though institutional investors—including California State Teachers’ Retirement System—added to their positions.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fifteen analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $32.6364.

BCAX has been the topic of a number of recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Wedbush lifted their price objective on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Bicara Therapeutics in a report on Thursday. BTIG Research boosted their price target on shares of Bicara Therapeutics from $28.00 to $39.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Finally, BMO Capital Markets started coverage on shares of Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an "outperform" rating and a $35.00 price objective for the company.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, CFO Ivan Hyep sold 12,500 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.97, for a total value of $349,625.00. Following the completion of the transaction, the chief financial officer owned 129,855 shares in the company, valued at $3,632,044.35. This represents a 8.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of the firm's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company's stock, valued at approximately $10,133,012.96. This represents a 2.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 125,500 shares of company stock valued at $3,479,986. 13.80% of the stock is owned by insiders.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently added to or reduced their stakes in BCAX. Engineers Gate Manager LP bought a new stake in Bicara Therapeutics in the second quarter worth about $499,000. Arizona State Retirement System purchased a new stake in shares of Bicara Therapeutics during the 2nd quarter worth approximately $241,000. Allianz Asset Management GmbH purchased a new stake in shares of Bicara Therapeutics during the 2nd quarter worth approximately $511,000. Corient Private Wealth LP bought a new stake in shares of Bicara Therapeutics in the 2nd quarter worth approximately $1,089,000. Finally, California State Teachers Retirement System raised its holdings in shares of Bicara Therapeutics by 6,742.2% in the 2nd quarter. California State Teachers Retirement System now owns 1,157,910 shares of the company's stock worth $34,378,000 after purchasing an additional 1,140,987 shares during the period.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $22.81 on Friday. The stock has a market capitalization of $1.51 billion, a P/E ratio of -7.36 and a beta of -0.82. The company has a 50-day moving average price of $25.89 and a 200-day moving average price of $22.98. Bicara Therapeutics has a 1 year low of $10.30 and a 1 year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.82). As a group, equities research analysts anticipate that Bicara Therapeutics will post -3.51 earnings per share for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.